Biotechnology news

• Curing Cancer: Advancements and What is Yet to Come

  08-02-2017 22:26
  
   
  Last month, MIT Technology Review reported “Two Infants Treated with Universal Immune Cells Have Their Cancer Vanish.” UK doctors treated the babies with genetically engineered T-cells from another person, known as CAR-T, as recounted in Science Translational Medicine.
  The London treatment is notable for involving the most extensively engineered cells ever given to a patient, with a total of four genetic changes, two of them introduced by gene editing using a method called TA
  
  Read more

• BIO Officially Opens Registration for the 2017 World Congress on Industrial Biotechnology

  08-02-2017 20:00
  
  We are  pleased to announce BIO’s World Congress on Industrial Biotechnology is the world’s largest industrial biotechnology conference that brings together from across the globe business leaders, investors, academics and policymakers in the biofuels, biobased products, renewable chemicals, synthetic biology, food ingredients and biomass sectors. The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Canada. Registra
  
  Read more

• Nano-CRISPR Packages Attain 90% Delivery Rate with Engineered Cas9

  08-02-2017 16:24
  Neither the cell membrane nor the cytoplasm nor the nuclear membrane stays these couriers from the swift completion of their appointed rounds. “These couriers” are nanoparticles that carry Cas9-ribonucleoprotein (RNP) complexes into the cytoplasm and nucleus of target cells, and do so with uncommon efficiency.
  Newly developed by scientists in Vincent Rotello's laboratory at the University of Massachusetts, Amherst, the nanoparticles are significant because they could enhance the effe
  
  Read more

• Renova Licenses Janssen's IND File for Stresscopin

  08-02-2017 16:17
  Renova Therapeutics has licensed rights to Janssen Pharmaceuticals’ IND file for stresscopin, a hormone involved in responses to physiological stress, with the goal of advancing the program as a treatment for a form of heart failure.The value of the license was not disclosed by Renova, which announced the agreement with Janssen earlier this week.Renova’s candidate, RT-400, is a peptide infusion treatment indicated for Acute Decompensated Heart Failure (ADHF), which accounts for appro
  
  Read more

• Advertisement

• Best Practices for Communication Between FDA and IND Sponsors During Drug Development

  08-02-2017 15:58
  
  The FDA recently released an online course to provide insights to drug sponsors on communicating with the FDA during drug development.  The hour-long course, Best Practices for Communication Between FDA and IND Sponsors During Drug Development, is designed to describe the best practices and procedures for timely, transparent, and effective communications between IND sponsors and FDA at critical junctures in drug development.
  After completing the course, IND sponsors are expected to have a
  
  Read more

• Chan Zuckerberg Biohub Awards $50M+ to 47 Investigators

  08-02-2017 15:28
  The Chan Zuckerberg Biohub (CZ Biohub) said today it will commit more than $50 million to fund human disease research by its first cohort of 47 investigators from the faculty of the University of California, Berkeley, Stanford University, and the University of California, San Francisco (UCSF).Each investigator will receive a five-year appointment and up to $1.5 million toward life science research in their areas of expertise. CZ Biohub said the investigators were selected from several academic d
  
  Read more

• Takeda to Support Koch Institute Immuno-Oncology Research with $1M Gift

  08-02-2017 14:38
  Takeda Pharmaceutical has given a two-year, $1 million gift to the Koch Institute for Integrative Cancer Research at MIT toward immuno-oncology research, the Institute and the pharma firm said today.
  The gift will support research intended to build on Institute studies focused on investigating the role of the immune response in cancer and developing potential novel treatments, Takeda and the Koch Institute said.
  According to the Institute, its investigators are exploring the relationship between
  
  Read more

• New DNA Repair Finding Could Lead to Novel Antibacterial Drugs

  08-02-2017 14:16
  Researchers from the University of North Carolina School of Medicine say they have have confirmed and clarified the key molecular details of one of a key DNA repair system known as nucleotide excision repair. Using an advanced sequencing technique to map and analyze DNA damage, the scientists demonstrated the functions in bacterial cells of two important excision repair proteins: Mfd and UvrD."The biochemical mechanisms of these proteins have been known for years from experiments involving
  
  Read more

• Advertisement

• Investors Pledge £5M for Nemaura's Solid-Dosage Transdermal Needle Platform

  08-02-2017 13:17
  U.K. biotech Nemaura Pharma reported securing funding commitments totalling £5 million ($6.2 million) from private investors to support the continued development of its Micro-Patch™ technology for delivering a solid dosage formulated hormone biologic.Nemaura’s Micro-Patch platform uses a retractable microneedle to deposit solid formulations of drugs, including biologics and vaccines, under the skin. Developed to allow self-administration by patients, the technology could help t
  
  Read more

• FDA Okays Amgen's Calcimimetic for Secondary HPT in Hemodialysis Patients

  08-02-2017 11:44
  Amgen’s injectable calcimimetic, Parsabiv™ (etelcalcetide), was approved by FDA for treating secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) who are receiving hemodialysis. Amgen currently markets its Sensipar®/Mimpara® (cinacalcet) tablets in the U.S. and other markets for the same indication. The firm says Parsabiv is the first therapy to be approved for the secondary HPT indication in 12 years. The treatment is also the only calcimim
  
  Read more

Follow @Biotech_News_AU on Twitter!